Literature DB >> 26976947

Antipsychotic prescription amongst hospitalized patients with dementia.

P Gallagher1, D Curtin1, A de Siún2, E O'Shea2, S Kennelly3, D O'Neill3, S Timmons2.   

Abstract

BACKGROUND: Antipsychotic drugs are used to treat behavioural and psychological symptoms of dementia, despite significant safety concerns regarding increased risk of stroke and mortality. The numbers of patients with dementia and related behavioural symptoms being treated in acute hospitals is increasing. AIM: (i) to determine pre-admission and in-hospital prevalence of antipsychotic use in a national sample of patients with dementia and acute illness; (ii) identify reasons for antipsychotic use; (iii) assess features of the ward environment which impact on patients with dementia; (iv) determine availability of dementia-specific policies, training, appraisal and mentorship programs which influence service delivery. DESIGN AND METHODS: Four-part standardized audit in 35 public acute hospitals comprising (i) retrospective healthcare record review (n = 660); (ii) prospective assessment of ward environment (n = 77); (iii) ward organization interview with clinical managers (n = 77); (iv) hospital organisation interview with senior managers (n = 35).
RESULTS: Antipsychotic drugs were prescribed to 29% of patients with dementia before hospitalization and to 41% during hospitalization; one quarter received new or additional prescriptions. Assessments for delirium (45%), dementia symptoms (39%), mood (26%), mental state (64%) and distress-provoking factors (3%) were suboptimal. Drug indications were documented in 78%. Non-pharmacological interventions were not documented. Most wards lacked environmental cues to promote orientation. Dementia-specific care pathways existed in 2 of 35 hospitals. Staff support and training programmes were suboptimal. 12% of patients were discharged with new antipsychotic prescriptions.
CONCLUSION: Antipsychotic medications are commonly prescribed for hospitalized patients with dementia in Ireland. Ward environments and dementia-related governance structures are suboptimal.
© The Author 2016. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26976947     DOI: 10.1093/qjmed/hcw023

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  4 in total

1.  Development of a tool for monitoring the prescribing of antipsychotic medications to people with dementia in general practice: a modified eDelphi consensus study.

Authors:  Aisling A Jennings; Naoihse Guerin; Tony Foley
Journal:  Clin Interv Aging       Date:  2018-10-23       Impact factor: 4.458

2.  A delicate balance: Psychotropic polypharmacy and anti-cholinergic use are correlated with fall incidence in Australian inpatients with dementia.

Authors:  Samuel X Tan; Sarah C Cameron; Lit Min Sam; Hugh Eigeland; Karen Hay; Eamonn Eeles; Kannan Natarajan
Journal:  Aging Med (Milton)       Date:  2021-08-27

3.  Anti-cholinergic drug burden in patients with dementia increases after hospital admission: a multicentre cross-sectional study.

Authors:  Annabelle Hook; Jessica L Randall; David A Codling; Judith R Harrison; Carla M Grubb; Natalie Ellis; Jack Wellington; Aayushi Hemmad; Agisilaos Zerdelis; Andrew R D Winnett; Benjamin D W Geers; Bethany Sykes; Charlotte N Auty; Cecilia Vinchenzo; Christiane E Thorburn; Daniella Asogbon; Emily Granger; Heather Boagey; Juliet Raphael; Kajal Patel; Kartik Bhargava; Mary-Kate M Dolley; Matthew J Maden; Mehdin M Shah; Qao M Lee; Ratnaraj Vaidya; Simran Sehdev; Sneha Barai; Sophie Roche; Uzair Khalid
Journal:  BMC Geriatr       Date:  2022-10-06       Impact factor: 4.070

4.  Development of consumer information leaflets for deprescribing in older hospital inpatients: a mixed-methods study.

Authors:  Natali Jokanovic; Parisa Aslani; Sophie Carter; Mai Duong; Danijela Gnjidic; Jesse Jansen; David Le Couteur; Sarah Hilmer
Journal:  BMJ Open       Date:  2019-12-11       Impact factor: 2.692

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.